Drug Trial Radar · NCT03732781
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
May 27, 2020
Primary completion
May 14, 2025
Study completion May 14, 2025
Sponsor
- Lead sponsor
- Oncoinvent Solutions ASIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma following complete CRS (cytoreduction score CC-0) and HIPEC. The study consists of three different cohorts: * Dose escalation cohorts * Repeated injection cohorts * Expansion cohort
Conditions
- Peritoneal Carcinoma
- Colorectal Carcinoma
Interventions
RadspherinDrug
Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension. Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0.Time frame: 18 months
- Maximum Tolerated DoseTime frame: 21 Days
- Explore efficacy (expansion cohort)Time frame: 18 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Oslo University Hospital
Oslo, Norway
Akademiska
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.